FDA Approves Travere's FILSPARI for FSGS Treatment in Adults and Children 8+

Key Takeaways

• FDA approved FILSPARI on April 13, 2026, for treating FSGS in adults and pediatric patients aged 8 years and older
• The approval expands treatment options for focal segmental glomerulosclerosis, a rare kidney disease affecting protein filtration
• Travere also expects partner Chugai Pharmaceutical to submit regulatory applications for sparsentan in Japan during 2026

---

Travere Therapeutics announced significant regulatory progress in its first quarter 2026 financial results, highlighted by FDA approval of FILSPARI for focal segmental glomerulosclerosis (FSGS) treatment.

The U.S. Food and Drug Administration approved FILSPARI on April 13, 2026, to reduce proteinuria in adult and pediatric patients aged 8 years and older with FSGS without nephrotic syndrome. This approval represents a major milestone for Travere’s rare disease portfolio and provides new treatment options for patients with this challenging kidney condition.

FSGS is a rare kidney disease that affects the glomeruli, the tiny filters in the kidneys responsible for removing waste and excess fluid from blood. The condition leads to proteinuria, where excess protein leaks into urine, potentially progressing to kidney failure if left untreated.

International Expansion Plans

Beyond the U.S. market, Travere is positioning for global expansion through strategic partnerships. The company’s partner, Chugai Pharmaceutical, expects to submit a New Drug Application for sparsentan in Japan during 2026, potentially opening access to the Japanese market.

Travere maintains financial upside from these international partnerships, remaining eligible for milestone payments related to sparsentan’s regulatory processes and net sales achievements in licensed territories. The company also stands to receive tiered royalties from successful commercialization efforts.

Market Impact and Patient Access

The FILSPARI approval addresses a significant unmet medical need in nephrology, particularly for pediatric patients where treatment options remain limited. The inclusion of patients as young as 8 years old in the approval represents important progress for childhood kidney disease management.

For Travere Therapeutics, this approval strengthens its position in the rare disease market and validates its focus on nephrology therapeutics. The company’s dual-track approach of direct U.S. commercialization and international partnerships through licensing agreements provides multiple revenue streams and risk mitigation.

---

Frequently Asked Questions

What does this FDA approval mean for FSGS patients?

The FILSPARI approval provides a new treatment option for adults and children 8+ with FSGS to reduce proteinuria, addressing a significant unmet need in rare kidney disease treatment.

When will FILSPARI be available to patients?

Following the April 13, 2026 FDA approval, FILSPARI should become commercially available shortly, though specific launch timing depends on manufacturing and distribution preparations.

How does FILSPARI compare to existing FSGS treatments?

FILSPARI offers a targeted approach to reducing proteinuria in FSGS patients, though specific comparative effectiveness data would need to be evaluated against current standard-of-care treatments.